Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
34 Results Found
Report finds launch prices for new drugs are significantly higher, exceed inflation
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released Oct. 23 by the Institute for Clinical and Economic Review.
Administration announces agreement with Pfizer to lower drug costs
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by other developed nations — wh
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts to impose rebate models within the 340B Drug Pricing Program, saying the actions may violate antitrust laws.
HHS announces access to real-time drug pricing, changes to prior authorization
The Department of Health and Human Services today announced prescription drug reforms
White House announces steps for drug manufacturers to meet ‘most favored nation’ pricing
The Trump administration today
HHS announces new 340B Rebate Model Pilot Program
The Department of Health and Human Services today issued a
Commerce Department to investigate imports of pharmaceuticals, semiconductors
The Department of Commerce yesterday released notices announcing national security investigations on imports of
HHS says pricing targets identified for drug manufacturers to meet ‘most favored nation’ requirements
The Department of Health and Human Services today announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy requirements of the Trump administration’s executive order allowing consumers to make direct purchases from drug manufacturers at “most favored nation” pricing, the lowest cost paid for the same medications in an Organization for Economic Co-operation and Development country with a gross domestic product per capita that is at least 60% of the U.S. GDP per capita.
CMS releases draft guidance for third cycle of Medicare drug price negotiations
The Centers for Medicare & Medicaid Services May 12 released
White House announces executive order establishing ‘most favored nation’ drug pricing
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at “most favored nation” pricing, the lowest cost paid for the same medications in other countries.